Gene therapy for metachromatic leukodystrophy and Gaucher disease

Research output: Contribution to journalArticle

Abstract

Lysosomal storage disorders (LSD(S)) are genetic disorders due to the deficiencies of lysosomal enzymes and resulting in the intracellular accumulation of toxic substrates in different organs, including the Central Nervous System (CNS). Currently, only symptomatic treatments are available for a number of these disorders. In fact, BMT has been carried out for several lysosomal storage diseases, and while normalized levels of enzymatic activity are typically observed in peripheral blood leukocytes after successful BMT, reports have varied concerning improvements in the neuropsychological status of patients with CNS involvement. Therefore, gene therapy might be a route to be pursued for the treatment of these diseases. This review describes possible approaches for gene therapy of two of the most frequent LSD: Metachromatic Leukodystrophy and Gaucher disease.

Original languageEnglish
Pages (from-to)236-241
Number of pages6
JournalMinerva Biotecnologica
Volume9
Issue number4
Publication statusPublished - Dec 1997

Fingerprint

Metachromatic Leukodystrophy
Gene therapy
Gaucher Disease
Genetic Therapy
Central Nervous System
Neurology
Lysosomal Storage Diseases
Lysergic Acid Diethylamide
Inborn Genetic Diseases
Poisons
Leukocytes
Blood
Enzymes
Therapeutics
Substrates

Keywords

  • Gaucher's disease
  • Gene therapy
  • Metachromatic leukodystrophy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Gene therapy for metachromatic leukodystrophy and Gaucher disease. / Severini, Giovanna Maria.

In: Minerva Biotecnologica, Vol. 9, No. 4, 12.1997, p. 236-241.

Research output: Contribution to journalArticle

@article{03830fbb31b3447ebdf640a0c9512344,
title = "Gene therapy for metachromatic leukodystrophy and Gaucher disease",
abstract = "Lysosomal storage disorders (LSD(S)) are genetic disorders due to the deficiencies of lysosomal enzymes and resulting in the intracellular accumulation of toxic substrates in different organs, including the Central Nervous System (CNS). Currently, only symptomatic treatments are available for a number of these disorders. In fact, BMT has been carried out for several lysosomal storage diseases, and while normalized levels of enzymatic activity are typically observed in peripheral blood leukocytes after successful BMT, reports have varied concerning improvements in the neuropsychological status of patients with CNS involvement. Therefore, gene therapy might be a route to be pursued for the treatment of these diseases. This review describes possible approaches for gene therapy of two of the most frequent LSD: Metachromatic Leukodystrophy and Gaucher disease.",
keywords = "Gaucher's disease, Gene therapy, Metachromatic leukodystrophy",
author = "Severini, {Giovanna Maria}",
year = "1997",
month = "12",
language = "English",
volume = "9",
pages = "236--241",
journal = "Minerva Biotecnologica",
issn = "1120-4826",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Gene therapy for metachromatic leukodystrophy and Gaucher disease

AU - Severini, Giovanna Maria

PY - 1997/12

Y1 - 1997/12

N2 - Lysosomal storage disorders (LSD(S)) are genetic disorders due to the deficiencies of lysosomal enzymes and resulting in the intracellular accumulation of toxic substrates in different organs, including the Central Nervous System (CNS). Currently, only symptomatic treatments are available for a number of these disorders. In fact, BMT has been carried out for several lysosomal storage diseases, and while normalized levels of enzymatic activity are typically observed in peripheral blood leukocytes after successful BMT, reports have varied concerning improvements in the neuropsychological status of patients with CNS involvement. Therefore, gene therapy might be a route to be pursued for the treatment of these diseases. This review describes possible approaches for gene therapy of two of the most frequent LSD: Metachromatic Leukodystrophy and Gaucher disease.

AB - Lysosomal storage disorders (LSD(S)) are genetic disorders due to the deficiencies of lysosomal enzymes and resulting in the intracellular accumulation of toxic substrates in different organs, including the Central Nervous System (CNS). Currently, only symptomatic treatments are available for a number of these disorders. In fact, BMT has been carried out for several lysosomal storage diseases, and while normalized levels of enzymatic activity are typically observed in peripheral blood leukocytes after successful BMT, reports have varied concerning improvements in the neuropsychological status of patients with CNS involvement. Therefore, gene therapy might be a route to be pursued for the treatment of these diseases. This review describes possible approaches for gene therapy of two of the most frequent LSD: Metachromatic Leukodystrophy and Gaucher disease.

KW - Gaucher's disease

KW - Gene therapy

KW - Metachromatic leukodystrophy

UR - http://www.scopus.com/inward/record.url?scp=0030668802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030668802&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 236

EP - 241

JO - Minerva Biotecnologica

JF - Minerva Biotecnologica

SN - 1120-4826

IS - 4

ER -